Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial

Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial

<p><strong>Background:</strong> Sodium-glucose co-transporter-2 (SGLT2) inhibitors are recommended treatment for adults with chronic kidney disease (CKD), but uncertainty exists regarding their use in patients with frailty and/or multimorbidity, among whom polypharmacy is common. W...

Full description

Bibliographic Details
Main Authors:	Mayne, KM, Sardell, R, Staplin, N, Judge, P, Zhu, D, Sammons, E, Wanner, C, Emberson, J, Preiss, D, Landray, M, Baigent, C, Haynes, R, Herrington, W
Other Authors:	EMPA-KIDNEY Collaborative Group
Format:	Journal article
Language:	English
Published:	American Society of Nephrology 2024

Similar Items

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
by: Mayne, K, et al.
Published: (2024)

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
by: Staplin, N, et al.
Published: (2023)

Empagliflozin and cardiovascular outcomes in patients with chronic kidney disease: the EMPA-KIDNEY trial
by: Preiss, D, et al.
Published: (2022)

Effects of empagliflozin on fluid overload, weight and blood pressure in chronic kidney disease
by: Mayne, K, et al.
Published: (2023)

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
by: Herrington, W, et al.
Published: (2018)

Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
by: Herrington, W, et al.
Published: (2022)

Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA–KIDNEY
by: Nangaku, M, et al.
Published: (2024)

Empagliflozin in patients with chronic kidney disease
by: Herrington, WG, et al.
Published: (2022)

Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial
by: Herrington, W, et al.
Published: (2022)

Use of causal diagrams to inform the analysis and interpretation of observational studies: An example from the Study of Heart and Renal Protection (SHARP)
by: Staplin, N, et al.
Published: (2016)

Evidence for the prevention and treatment of stroke in dialysis patients
by: Herrington, W, et al.
Published: (2014)

Long-term effects of empagliflozin in patients with chronic kidney disease
by: Herrington, WG, et al.
Published: (2024)

Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial
by: David Fitchett, et al.
Published: (2021-12-01)

Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME
by: Pierpaolo Pellicori, et al.
Published: (2020-12-01)

Conventional and genetic evidence on the association between adiposity and chronic kidney disease
by: Zhu, P, et al.
Published: (2020)

Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial
by: Subodh Verma, et al.
Published: (2021-08-01)

Fibroblast growth factor-23 and risk of cardiovascular diseases: a Mendelian randomization study
by: Donovan, K, et al.
Published: (2022)

Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial
by: Haynes, R, et al.
Published: (2018)

Empagliflozin and Rapid Kidney Function Decline Incidence in Type 2 Diabetes: An Exploratory Analysis From the EMPA-REG OUTCOME Trial
by: Samy Hadjadj, et al.
Published: (2024-03-01)

Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)
by: Herrington, WG, et al.
Published: (2023)

The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial
by: Judge, PK, et al.
Published: (2024)

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
by: Storey, B, et al.
Published: (2017)

Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank
by: Zhu, P, et al.
Published: (2020)

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
by: Staplin, N, et al.
Published: (2023)

Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA‐REG OUTCOME® trial
by: Takashi Kadowaki, et al.
Published: (2019-05-01)

Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure
by: Hundertmark, MJ, et al.
Published: (2021)

Journey from EMPA-REG to CARMELINA to EMPEROR-Preserved: Empagliflozin/linagliptin in heart failure and diabetes
by: Sharvil S Gadve, et al.
Published: (2022-01-01)

Design and rationale of the EMPA‐VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure
by: Moritz J. Hundertmark, et al.
Published: (2021-08-01)

1. Effect of empagliflozin on cardiovascular death in subgroups by age: Results from EMPA-REG outcome
by: Mahmoud Elrouby, et al.
Published: (2017-10-01)

Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?
by: Ampudia-Blasco FJ, et al.
Published: (2017-01-01)

Impact of primary kidney disease on the effects of empagliflozin in patients with CKD
by: Judge, PK, et al.
Published: (2023)

Conventional and genetic evidence on the association between adiposity and CKD
by: Zhu, P, et al.
Published: (2020)

Are the cardiovascular risk reductions seen with empagliflozin in the EMPA-REG OUTCOME trial explained by conventional cardiovascular risk factors?
by: Coleman, R, et al.
Published: (2017)

Polypharmacy Management in Elderly Patients with Multimorbidity
by: Wanyu PAN, Chunhui ZHANG, Zhenxiang ZHANG, Jing CHEN, Yongxia MEI, Beilei LIN, Shaoyang WANG, Qinghua ZHAI
Published: (2022-05-01)

Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy
by: Storey, B, et al.
Published: (2018)

Assessment of cardiac energy metabolism, function, and physiology in patients with heart failure taking empagliflozin: the randomized, controlled EMPA-VISION trial
by: Hundertmark, MJ, et al.
Published: (2023)

Multimorbidity or Polypharmacy: Two Sides of the Same Coin?
by: Carol Sinnott, et al.
Published: (2015-01-01)

Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD
by: Lamprea-Montealegre, J, et al.
Published: (2019)

Frailty modifies the effect of polypharmacy and multimorbidity on the risk of death among nursing home residents: Results from the SHELTER study
by: Maria Beatrice Zazzara, et al.
Published: (2023-02-01)

Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease
by: Herrington, W, et al.
Published: (2016)